Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel.
Narita S, Kimura T, Hatakeyama S, Hata K, Yanagisawa T, Maita S, Chiba S, Sato H, Kashima S, Koizumi A, Yamamoto R, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Suzuki T, Ohyama C, Egawa S, Habuchi T.
Narita S, et al. Among authors: kumazawa t.
Int J Clin Oncol. 2022 Sep;27(9):1477-1486. doi: 10.1007/s10147-022-02203-y. Epub 2022 Jun 24.
Int J Clin Oncol. 2022.
PMID: 35748967